Nice University Hospital Launches Clinical Study on Purine Metabolism Pathway and PPi Measurement in PXE Patients
Pathophysiology and Importance of the Research
Pseudoxanthoma Elasticum (PXE) is a rare autosomal recessive genetic disorder affecting approximately 1 in 50,000 individuals, characterized by progressive calcification of the skin, retina, and arterial walls. The disease results from mutations in the ABCC6 gene, leading to deficient extracellular secretion of adenosine triphosphate (ATP). ATP deficiency impairs the production of inorganic pyrophosphate (PPi), an inhibitor of calcification, thereby promoting excessive calcium deposition in vessels and soft tissues. The PURI-PXE clinical study is designed to directly track this purine metabolism pathway in order to identify molecular-level biomarkers that could prevent and control vascular lesions.
PURI-PXE Clinical Trial Design
The PURI-PXE trial (NCT07323082), led by Nice University Hospital (Centre Hospitalier Universitaire de Nice) in France, was formally launched on January 20, 2026 to conduct an in‑depth analysis of how purine metabolic compounds affect vascular pathology in PXE patients. Rather than a simple drug administration study, this is a basic science investigation enrolling 45 participants (patients and matched controls) to precisely quantify plasma PPi and adenosine (ADO) levels and assess the activity of related enzymes (e.g., ENPP1, NT5E). The investigators aim for a primary completion date of January 15, 2027, with the objective of delineating the correlation between PPi/ADO concentrations and the actual Calcification Score. Metabolic data generated by this study are expected to enhance the reliability of biomarkers for future targeted therapeutics.
Global Competitive Landscape and Pipeline Trends
In the current PXE market, BioMarin Pharmaceutical (BMRN) – which acquired Inozyme Pharma – positions BMN 401 (formerly INZ‑701) as a leading competitive pipeline candidate. BMN 401 employs an ENPP1 enzyme replacement strategy to restore endogenous PPi levels; however, in May 2026 its Phase 3 pediatric ENPP1‑deficiency trial failed to meet several co‑primary endpoints related to bone healing, prompting a reassessment of its development plan. Concurrently, the TEMP trial is evaluating the efficacy of the stable PPi analogue etidronate, and the PROPHECI Phase 2 study is assessing an oral PPi supplement. The foundational clinical work at Nice University Hospital will provide robust validation of the pathogenic mechanisms within purine metabolism that these competing agents target.
Market Outlook and Investment Analysis
The global PXE market, encompassing over 160,000 potential patients, currently lacks any approved disease‑modifying therapy, representing a high‑unmet‑need blue‑ocean opportunity. Existing interventions are limited to ophthalmic symptom management, such as anti‑VEGF intravitreal injections to curb retinal neovascularization, and do not address the underlying calcification process. Consequently, a drug that can inhibit calcification is valued at several billions of dollars. If this foundational trial elucidates the regulatory mechanisms of purine metabolism, it could markedly increase the probability of success for therapeutics targeting metabolic enzymes. From an investor perspective, the study’s data—by providing novel biomarkers and alternative pathways—may offset the clinical uncertainty surrounding BMN 401.
The global market for the rare disease Pseudoxanthoma Elasticum (PXE), affecting approximately 160,000 patients, currently has no approved disease‑modifying therapy, making it an untapped segment where successful drug development could secure a monopoly position. The PURI‑PXE trial (NCT07323082) aims to delineate the relationship between the purine metabolism pathway—including ENPP1 and NT5E enzymes—and PPi and ADO levels, thereby establishing precise biomarker criteria for future drug development. In particular, as BioMarin Pharmaceutical’s ENPP1 enzyme therapy BMN 401 (formerly INZ‑701) is undergoing a value reassessment after failing to meet certain endpoints in a pediatric Phase 3 trial, this basic research serves as a milestone for exploring alternative metabolic pathways. In the short term, the patient‑control dataset expected for primary completion in January 2027 will provide a baseline for demonstrating the efficacy of metabolic modulators, while in the medium to long term it will serve as a benchmark to gauge the success of competing pipelines such as the Phase 2 PROPHECI program.
Source: ClinicalTrials.gov (api_ct)